230 related articles for article (PubMed ID: 35863740)
1. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Auletta JJ; Badawy SM; Bhatt N; Bhatt VR; Cahn JY; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Gale RP; Hashem H; Hashmi S; Hematti P; Hong S; Hossain NM; Inamoto Y; Lekakis LJ; Modi D; Patel S; Sharma A; Solomon S; Couriel DR
Transplant Cell Ther; 2022 Oct; 28(10):712.e1-712.e8. PubMed ID: 35863740
[TBL] [Abstract][Full Text] [Related]
2. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
[TBL] [Abstract][Full Text] [Related]
3. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
[TBL] [Abstract][Full Text] [Related]
6. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
7. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.
Boyiadzis M; Arora M; Klein JP; Hassebroek A; Hemmer M; Urbano-Ispizua A; Antin JH; Bolwell BJ; Cahn JY; Cairo MS; Cutler CS; Flowers ME; Gale RP; Herzig R; Isola LM; Jacobsohn DA; Jagasia MH; Klumpp TR; Lee SJ; Petersdorf EW; Santarone S; Spellman SR; Schouten HC; Verdonck LF; Wingard JR; Weisdorf DJ; Horowitz MM; Pavletic SZ
Clin Cancer Res; 2015 May; 21(9):2020-8. PubMed ID: 25348512
[TBL] [Abstract][Full Text] [Related]
8. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.
Chhabra S; Visotcky A; Pasquini MC; Zhu F; Tang X; Zhang MJ; Thompson R; Abedin S; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Douglas Rizzo J; Runaas L; Saber W; Shah NN; Shaw BE; Horowitz MM; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1876-1885. PubMed ID: 32653622
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
[TBL] [Abstract][Full Text] [Related]
11. Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease.
Schaar DA; Pirsl F; Holtzman N; Steinberg SM; Nashed J; Ruben C; Cowen EW; Mays JW; Mitchell S; Ostojic A; Munshi PN; Joe GO; Comis LE; Morton L; Pavletic SZ
Transplant Cell Ther; 2021 Nov; 27(11):937.e1-937.e7. PubMed ID: 34380090
[TBL] [Abstract][Full Text] [Related]
12. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.
Zecca M; Prete A; Rondelli R; Lanino E; Balduzzi A; Messina C; Fagioli F; Porta F; Favre C; Pession A; Locatelli F;
Blood; 2002 Aug; 100(4):1192-200. PubMed ID: 12149197
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR).
Gabriel M; Shaw BE; Brazauskas R; Chen M; Margolis DA; Sengelov H; Dahlberg A; Ahmed IA; Delgado D; Lazarus HM; Gibson B; Myers KC; Kamble RT; Abdel-Mageed A; Li CK; Flowers MED; Battiwalla M; Savani BN; Majhail N; Shaw PJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1320-1326. PubMed ID: 28411175
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
[TBL] [Abstract][Full Text] [Related]
17. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
[TBL] [Abstract][Full Text] [Related]
18. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study.
Soejima T; Shiohara M; Ishida Y; Inoue M; Hayakawa A; Sato A; Kamibeppu K; Atsuta Y; Yamashita T
Int J Hematol; 2021 Apr; 113(4):566-575. PubMed ID: 33386599
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
